Skip to Content

'
Eric Jonasch, MD

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3506
Phone: 713-792-2830

Education & Training

Degree-Granting Education

1988 McGill University, Montreal, Canada, BSc, Biochemistry

Postgraduate Training

6/1997-5/1999 Research Fellowship, Beth Israel Deaconess Medical Center, Boston, MA
7/1995-6/1997 Clinical Fellowship, New England Medical Center, Boston, MA
7/1995-5/1997 Research Fellowship, Hematology/Oncology, New England Medical Center, Boston, MA
7/1992-6/1995 Clinical Residency, Internal Medicine, Royal Victoria Hospital, Montreal, Canada
9/1988-5/1992 MDCM, McGill Medical School, Montreal, Canada

Board Certifications

11/2005 Internal Medicine, American Board of Internal Medicine
11/2000 Medical Oncology American Board of Internal Medicine
2000 Oncology, Royal College of Physicians & Surgeons of Canada
2000 Medicine, Royal College of Physicians & Surgeons of Canada
11/1999 Hematology, American Board of Internal Medicine

Experience/Service

Academic Appointments

Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX, 9/2002-8/2009

Administrative Appointments/Responsibilities

Fellowship Program Director, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present
Director, Von Hippel Lindau (VHL) Clinical Center, Houston, TX, 2003-present

Other Appointments/Responsibilities

Member, Graduate School of Biomedical Science, The University of Texas, Health Science Center, Houston, TX, 1/2004-present

Consultantships

Medical Advisory Board Member, Von Hippel Lindau (VHL) Family Alliance, Boston, MA, 2007-present
Member, Kidney Cancer Association Medical Advisory Board, Chicago, Illinois, 2004-present

Honors and Awards

2009 Young Texans Against Cancer Research Award
2008-present Renal Cell Carcinoma Translational Research, American University-Beirut
1997 Molecular Biology Research Seminar for Young Investigators, American Association for Cancer Research

Professional Memberships

American Association for Cancer Research (AACR)
Member, 1/1997-present
American Society of Clinical Oncology (ASCO)
Member, 7/2000-present
National Comprehensive Cancer Network (NCCN)
Member, Kidney & Testicular Cancers Panel, 3/2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Simon JM, Hacker KE, Singh D, Brannon AR, Parker JS, Weiser M, Ho TH, Kuan PF, Jonasch E, Furey TS, Prins JF, Lieb JD, Rathmell WK, Davis IJ. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res. e-Pub 10/24/2013. PMID: 24158655.
2. Rini BI, Melichar B, Ueda T, Grünwald V, Fishman MN, Arranz JA, Bair AH, Pithavala YK, Andrews GI, Pavlov D, Kim S, Jonasch E. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol. e-Pub 10/2013. PMID: 24140184.
3. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49(15):3169-75, 10/2013. e-Pub 6/26/2013. PMID: 23810246.
4. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules. J Urol. e-Pub 9/6/2013. PMID: 24018239.
5. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes. BJU Int. e-Pub 8/23/2013. PMID: 24053120.
6. Donat SM, Diaz M, Bishoff JT, Coleman JA, Dahm P, Derweesh IH, Herrell SD, Hilton S, Jonasch E, Lin DW, Reuter VE, Chang SS. Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. J Urol 190(2):407-16, 8/2013. e-Pub 5/2013. PMID: 23665399.
7. Garcia-Donas J, Rodriguez-Antona C, Jonasch E. Molecular markers to predict response to therapy. Semin Oncol 40(4):444-58, 8/2013. PMID: 23972708.
8. Sun M, Zhou T, Jonasch E, Jope RS. DDX3 regulates DNA damage-induced apoptosis and p53 stabilization. Biochim Biophys Acta 1833(6):1489-97, 6/2013. e-Pub 3/5/2013. PMID: 23470959.
9. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int. e-Pub 3/19/2013. PMID: 23510233.
10. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness Uncertainty and Quality of Life of Patients with Small Renal Tumors Undergoing Watchful Waiting: A 2-year Prospective Study. Eur Urol. e-Pub 2/9/2013. PMID: 23419322.
11. Zhao Q, Caballero OL, Davis ID, Jonasch E, Tamboli P, Yung WK, Weinstein JN, Strausberg RL, Yao J, Shaw K. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas. Clin Cancer Res. e-Pub 2/26/2013. PMID: 23444225.
12. Larkin J, Fishman M, Wood L, Negrier S, Olivier K, Pyle L, Gorbunova V, Jonasch E, Andrews L, Staehler M. Axitinib for the Treatment of Metastatic Renal Cell Carcinoma: Recommendations for Therapy Management to Optimize Outcomes. Am J Clin Oncol. e-Pub 1/2013. PMID: 23357974.
13. Sircar K, Rao P, Jonasch E, Monzon FA, Tamboli P. Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features. Chin J Cancer. e-Pub 12/2012. PMID: 23237216.
14. Guo H, Liu W, Ju Z, Tamboli P, Jonasch E, Mills GB, Lu Y, Hennessy B, Tsavachidou D. An efficient procedure for protein extraction from formalin-fixed, paraffin-embedded tissues for reverse phase protein arrays. Proteome Sci 10(1). e-Pub 9/24/2012. PMID: 23006314.
15. Verma J, Jonasch E, Allen PK, Weinberg JS, Tannir N, Chang EL, Mahajan A. The Impact of Tyrosine Kinase Inhibitors on the Multimodality Treatment of Brain Metastases From Renal Cell Carcinoma. Am J Clin Oncol. e-Pub 8/2012. PMID: 22892430.
16. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. Eur Urol. e-Pub 6/27/2012. PMID: 22771265.
17. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Locally Advanced and Metastatic Nonclear Cell Renal Cell Carcinoma. Am J Clin Oncol. e-Pub 6/14/2012. PMID: 22706175.
18. Jonasch E, Motzer RJ. Ten years of progress in renal cell carcinoma. J Natl Compr Canc Netw 10(6):690-3, 6/1/2012. PMID: 22679113.
19. Griffioen AW, Mans L, de Graaf A, Nowak-Sliwinska P, de Hoog C, de Jong T, Vyth F, van Beijnum JR, Bex A, Jonasch E. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin Cancer Res. e-Pub 5/9/2012. PMID: 22573349.
20. Jonasch E, Futreal A, Davis I, Bailey S, Kim WY, Brugarolas J, Giaccia AJ, Kurban G, Pause A, Frydman J, Zurita A, Rini BI, Sharma P, Atkins M, Walker C, Rathmell WK. State-of-the-science: An update on renal cell carcinoma. Mol Cancer Res. e-Pub 5/2012. PMID: 22638109.
21. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S, Hancock SL, Hudes GR, Jonasch E, Kuzel TM, Lau C, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Wang J, Wilder RB. Testicular cancer. J Natl Compr Canc Netw 10(4):502-35, 4/1/2012. PMID: 22491049.
22. Kim BY, Jonasch E, McCutcheon IE. Pazopanib therapy for cerebellar hemangioblastomas in von Hippel-Lindau disease : Case report. Target Oncol. e-Pub 2/29/2012. PMID: 22374327.
23. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One 7(8):e42324, 2012. e-Pub 8/2012. PMCID: PMC3409855.
24. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 22(12):2661-6, 12/2011. PMID: 22105611.
25. Ho TH, Jonasch E. Axitinib in the treatment of metastatic renal cell carcinoma. Future Oncol 7(11):1247-53, 11/2011. PMID: 22044199.
26. Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR, Jonasch E, Josephson D, Kuzel TM, Levine EG, Lin DW, Margolin KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG, Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J, Wilder RB. Kidney cancer. J Natl Compr Canc Netw 9(9):960-77, 9/1/2011. PMID: 21917622.
27. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM. Pilot Trial of Bone-Targeted Therapy Combining Zoledronate With Fluvastatin or Atorvastatin for Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. e-Pub 9/27/2011. PMID: 21958521.
28. Choueiri M, Tannir N, Jonasch E. Adjuvant and Neoadjuvant Therapy in Renal Cell Carcinoma. Curr Clin Pharmacol. e-Pub 8/9/2011. PMID: 21827393.
29. Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma. Curr Clin Pharmacol. e-Pub 8/9/2011. PMID: 21827388.
30. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol. e-Pub 7/2011. PMID: 21725288.
31. Hagenkord JM, Gatalica Z, Jonasch E, Monzon FA. Clinical genomics of renal epithelial tumors. Cancer Genet 204(6):285-97, 6/2011. PMID: 21763625.
32. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther 11(6):913-20, 6/2011. PMID: 21707288.
33. Richey SL, Culp SH, Jonasch E, Matin SF, Wood CG, Tannir NM. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol 22(5):1243, 5/2011. PMID: 21521725.
34. Chapin BF, Delacroix SE, Culp SH, Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. Eur Urol. e-Pub 5/2011. PMID: 21621907.
35. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. e-Pub 4/4/2011. PMID: 21464158.
36. Choueiri M, Jonasch E. Have Molecularly Targeted Therapies Improved Overall Survival in Renal Cell Carcinoma? Curr Oncol Rep. e-Pub 4/2011. PMID: 21455732.
37. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer. e-Pub 4/2011. PMID: 21484781.
38. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre. BJU Int 107(5):741-7, 3/2011. e-Pub 9/21/2010. PMID: 21355978.
39. Hudes GR, Carducci MA, Choueiri TK, Esper P, Jonasch E, Kumar R, Margolin KA, Michaelson MD, Motzer RJ, Pili R, Roethke S, Srinivas S. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J Natl Compr Canc Netw 9 Suppl 1:S1-29, 2/2011. PMID: 21335444.
40. Schöffski P, Garcia JA, Stadler WM, Gil T, Jonasch E, Tagawa ST, Smitt M, Yang X, Oliner KS, Anderson A, Zhu M, Kabbinavar F. A phase II study of the efficacy and safety of AMG 102 in patients with metastatic renal cell carcinoma. BJU Int. e-Pub 12/13/2010. PMID: 21156020.
41. Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable Remission of Metastatic Renal Cell Carcinoma With Gemcitabine and Capecitabine After Failure of Targeted Therapy. J Clin Oncol. e-Pub 12/2010. PMID: 21172884.
42. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther 10(12):1883-9, 12/2010. PMID: 21110755.
43. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. J Urol. e-Pub 12/2010. PMID: 21167518.
44. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. e-Pub 11/2010. PMID: 21115604.
45. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous Biopsy of Primary Tumor in Metastatic Renal Cell Carcinoma to Predict High Risk Pathological Features: Comparison With Nephrectomy Assessment. J Urol 184(5):1877-81, 11/2010. e-Pub 9/17/2010. PMID: 20850148.
46. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radiofrequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol 184(5):1882-7, 11/2010. e-Pub 9/17/2010. PMID: 20846689.
47. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary Tumor Response to Targeted Agents in Patients with Metastatic Renal Cell Carcinoma. Eur Urol. e-Pub 10/15/2010. PMID: 20952123.
48. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. Gene and protein expression markers of response to combined antiangiogenic and epiderman growth factor targeted therapy in renal cell carcinoma. Ann Oncol 21(8):1599-606, 8/2010. e-Pub 1/2010. PMID: 20089566.
49. Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T, van Poppel H, Wood CG. Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. Eur Urol. e-Pub 8/2010. PMID: 20828919.
50. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Cin PD, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. e-Pub 7/21/2010. PMID: 20665500.
51. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol 5(2):113-8, 6/2010. e-Pub 7/2010. PMID: 20625844.
52. Jonasch E. Prognostic and predictive factors in the targeted therapy era: filling in the blanks. Curr Oncol Rep 12(3):143-5, 5/2010. PMID: 20425072.
53. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 1/1/2010. e-Pub 10/2009. PMID: 19862815.
54. Montero AJ, Diaz-Montero CM, Millikan RE, Liu J, Do KA, Hodges S, Jonasch E, McIntyre BW, Hwu P, Tannir N. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-{alpha}: association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 10/2009. e-Pub 6/18/2009. PMID: 19541791.
55. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-4081, 9/1/2009. e-Pub 7/27/2009. PMID: 19636008.
56. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456-60, 8/2009. e-Pub 3/2009. PMID: 19338544.
57. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 7(6):618-30, 6/2009. PMID: 19555584.
58. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J. NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. J Natl Compr Canc Netw 7(6):672-93, 6/2009. PMID: 19555582.
59. Zurita AJ, Jonasch E, Wu HK, Tran HT, Heymach JV. Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer 115(10 Suppl):2346-54, 5/2009. PMID: 19402074.
60. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood CG, Sandler CM. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics 29(3):741-54; discussion 755-7, May-Jun, 5/2009. PMID: 19448113.
61. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 115(9):1859-66, 5/2009. PMID: 19241453.
62. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. A randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma. Urology 73(2):337-41, 2/2009. e-Pub 10/31/2008. PMID: 18950837.
63. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94(2):386-91, 2/2009. e-Pub 11/18/2008. PMID: 19017755.
64. Dubauskas Z, Kunishige J, Prieto VG, Jonasch E, Hwu P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7(1):20-3, 1/2009. PMID: 19213663.
65. Kim J, Jonasch E, Alexander A, Short JD, Cai S, Wen S, Tsavachidou D, Tamboli P, Czerniak BA, Do KA, Wu KJ, Marlow LA, Wood CG, Copland JA, Walker CL. Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma. Clin Cancer Res 15(1):81-90, 1/2009. PMID: 19118035.
66. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther 7(10):1619-27, 10/2008. e-Pub 10/3/2008. PMID: 19018165.
67. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 9/2008. e-Pub 7/17/2008. PMID: 18635226.
68. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 14(5):315-9, Sep-Oct, 9/2008. PMID: 18836336.
69. Matin SF, Ahrar K, Wood CG, Daniels M, Jonasch E. Patterns of intervention for renal lesions in von Hippel-Lindau disease. BJU Int 102(8):940-45, 9/2008. e-Pub 5/2008. PMID: 18485044.
70. Jonasch E, Stadler WM, Bukowski RM, Hayes TG, Varadhachary A, Malik R, Figlin RA, Srinivas S. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma. Cancer 113(1):72-7, 7/1/2008. PMID: 18484647.
71. Rich TA, Jonasch E, Matin S, Waguespack SG, Gombos DS, Santarpia L, Stolle C, Jimenez C. A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma. Cancer Invest 26(6):642-6, 7/2008. PMID: 18584357.
72. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180(1):94-8, 7/2008. e-Pub 5/15/2008. PMID: 18485389.
73. Margulis V, Wood CG, Jonasch E, Matin SF. Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors. Curr Oncol Rep 10(3):253-8, 5/2008. PMID: 18765156.
74. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8):1336-41, 4/22/2008. e-Pub 3/25/2008. PMCID: PMC2361701.
75. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology. J Urol 178(5):1896-1900, 11/2007. e-Pub 9/17/2007. PMID: 17868729.
76. Kassouf W, Sanchez-Ortiz R, Tamboli P, Jonasch E, Merchant MM, Spiess PE, Wood CG. Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience. Urology 69(5):835-8, 5/2007. PMID: 17482917.
77. Kader AK, Tamboli P, Luongo T, Matin SF, Bell K, Jonasch E, Swanson DA, Wood CG. Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience. J Urol 177(3):855-60; discussion 860-1, 3/2007. PMID: 17296358.
78. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 11/1/2006. PMID: 17029276.
79. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar K, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J, National Comprehensive Cancer Network. Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(10):1072-81, 11/2006. PMID: 17112454.
80. Motzer RJ, Bolger GB, Boston B, Carducci MA, Fishman M, Hancock SL, Hauke RJ, Hudes GR, Jonasch E, Kantoff P, Kuzel TM, Lange PH, Levine EG, Logothetis C, Margolin KA, Pohar KS, Redman BG, Robertson CN, Samlowski WE, Sheinfeld J, National Comprehensive Cancer Network. Testicular cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(10):1038-58, 11/2006. PMID: 17112452.
81. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 8/1/2006. PMID: 16795067.
82. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 106(10):2143-7, 5/15/2006. PMID: 16598751.
83. Delman KA, Shapiro SE, Jonasch EW, Lee JE, Curley SA, Evans DB, Perrier ND. Abdominal visceral lesions in von Hippel-Lindau disease: incidence and clinical behavior of pancreatic and adrenal lesions at a single center. World J Surg 30(5):665-9, 5/2006. PMID: 16617420.
84. Linette GP, Zhang D, Hodi FS, Jonasch EP, Longerich S, Stowell CP, Webb IJ, Daley H, Soiffer RJ, Cheung AM, Eapen SG, Fee SV, Rubin KM, Sober AJ, Haluska FG. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res 11(21):7692-9, 11/1/2005. PMID: 16278389.
85. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol 16(5):679-88, 5/2005. PMID: 15872323.
86. Highshaw RA, Vakar-Lopez F, Jonasch E, Yasko AW, Matin SF. Port-site metastasis: the influence of biology. Eur Urol 47(3):357-60, 3/2005. e-Pub 1/15/2005. PMID: 15716201.
87. Katz KA, Jonasch E, Hodi FS, Soiffer R, Kwitkiwski K, Sober AJ, Haluska FG. Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 15(1):77-82, 2/2005. PMID: 15714125.
88. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, Aldape K, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: validated targets in cancer? J Cell Biochem 92(6):1115-40, 8/15/2004. PMID: 15258897.
89. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-36, 11/15/2003. e-Pub 7/24/2003. PMID: 12881308.
90. Kim PN, Jonasch E, Mosterman BC, Mier JW, Janssen RA. Radicicol suppresses transformation and restores tropomyosin-2 expression in both ras- and MEK-transformed cells without inhibiting the Raf/MEK/ERK signaling cascade. Cell Growth Differ 12(11):543-50, 11/2001. PMID: 11714635.
91. Greenberg DB, Jonasch E, Gadd MA, Ryan BF, Everett JR, Sober AJ, Mihm MA, Tanabe KK, Ott M, Haluska FG. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 89(2):356-62, 7/15/2000. PMID: 10918166.
92. Jonasch E, Kumar UN, Linette GP, Hodi FS, Soiffer RJ, Ryan BF, Sober AJ, Mihm MC, Tsao H, Langley RG, Cosimi BA, Gadd MA, Tanabe KK, Souba W, Haynes HA, Barnhill R, Osteen R, Haluska FG. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J 6(3):139-45, May-Jun, 5/2000. PMID: 10882328.
93. Janssen RA, Veenstra KG, Jonasch P, Jonasch E, Mier JW. Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent. J Biol Chem 273(48):32182-6, 11/1998. PMID: 9822696.
94. Ng C, Wood C, Tannir N, Jonasch E, Alba F, Matin S. Active surveillance for management of an incidental renal mass in patients with or without an active nonrenal malignancy. Cancer. Submitted.

Invited Articles

1. Atkins M, George D, Jonasch, E. Immunotherapy of renal cell carcinoma. UptoDate, 2009.
2. Jonasch E. Current and emerging treatment options in advanced renal cell cancer. Adv Studies In Med 8(1):5-7, 2/2008.
3. Jonasch E. Presurgical therapy in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 7(1):73-8, 1/2007. PMID: 17187521.
4. Matin SF, Jonasch E. Targeting von Hippel-Lindau syndrome: the future is now. Future Oncol 2(3):321-3, 6/2006. PMID: 16787109.
5. Jonasch E. Melanoma: what the primary care physician needs to know. Primary Care Update for OB/GYNS 10(2):51-59, March-April, 2003.
6. Jonasch E. Melanoma vaccination: state-of-the-art and experimental approaches. Expert Rev Anticancer Ther 1(3):427-40, 10/2001. PMID: 12113109.
7. Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6(1):34-55, 2001. PMID: 11161227.

Editorials

1. Jonasch E. Prognostic models: from the fates to the future. Cancer 115(10):2028-30, 5/15/2009. PMID: 19288573.

Abstracts

1. Atkinson BJ, Kalra S, Wang X, Bathala T, Perpich J, Corn PG, Tannir NM, Jonasch E. Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single-center experience. J Clin Oncol (#e15611), 12/2013.
2. Atkinson BJ, Kalra S, Wang X, Tannir NM, Jonasch E. A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule. J Clin Oncol (#381), 10/2013.
3. Rini BI, Gruenwald V, Fishman MN, Melichar B, Ueda T Bair AH, Chen Y, Bycott PW, Pavlov D, Kim S, Jonasch E. Axitinib with or without dose titration for first-line metastatic renal cell carcinoma (mRCC): Unblinded results from a randomized phase II study. J Clin Oncol (#LBA349), 10/2013.
4. Jonasch E, Thakur S, Sircar K, Tamboli P, Tannir NM, Monzon FA. Impact of chromosomal copy number variation on outcome in metastatic clear cell renal cell carcinoma patients treated with antiangiogenic agents. J Clin Oncol (#393), 10/2013.
5. Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver KW, Kumar Pal S, Scott JA, Vogelzang NJ. Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States. J Clin Oncol (#424), 10/2013.
6. Jonasch E, Corn PG, Pagliaro LC, Lara P, Wang X, Do KA, Garza R, Bird S, Drabick JJ, Marcott V, Quinn D, Doyle A, Tannir NM. Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients. J Clin Oncol (#4517), 10/2013.
7. Vogelzang NJ, Signorovitch JE, Lin PL., Liu Z, Culver KW, Scott JA, Kumar Pal S, Jonasch E. Sequential use of targeted therapies for metastatic renal cell carcinoma: A physician survey and chart review of community oncology practices in the United States. J Clin Oncol (#418), 10/2013.
8. Ho TH, Warneke CL, Hoang A, Tamboli P, Wang F, Jonasch E. The role of FGF signaling in VEGF-pathway targeted therapy resistance: Data from patients and model systems. J Clin Oncol (#386), 10/2013.
9. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do KA, Wang X, Marcott VD, Matin SF, Tannir NM. Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. J Clin Oncol (#371), 10/2013.
10. Burnight T, Wood CG, Tannir NM, Jonasch E, Pisters LL, Matin SF, Spelman A, Wei Q, Cohen L. A randomized controlled trial of expressive writing for patients with renal cell carcinoma (RCC). J Clin Oncol (#9029), 10/2012.
11. Rini BI, Grünwald V, Fishman MN, Melichar B, Ueda T, Karlov PA, Bair AH, Chen Y, Kim S, Jonasch E. Axitinib for first-line metastatic renal cell carcinoma (mRCC): Overall efficacy and pharmacokinetic (PK) analyses from a randomized phase II study. J Clin Oncol (#4503), 10/2012.
12. Bex A, Griffioen A W, Mans LA, de Graaf AMA, Sliwinska P N, Bosch S, de Hoog C, de Jong TAM, Dreese FV, Jonasch E. Effect of preoperative antiangiogenic treatment and subsequent discontinuation on angiogenesis in the primary tumor in patients with RCC. J Clin Oncol (#350), 10/2012.
13. Cauley DH, Atkinson BJ, Ng CS, Wang X, Xiao L, Corn PG, Jonasch E, Tannir NM. Everolimus (E) and temsirolimus (T) associated penumonitis (P) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol (#401), 10/2012.
14. Chapin BF, Delaxroix SE, Kenney PA, Nogueras Gonzalez GM, Tamboli P, Jonasch E, Tannir NM, Wood CG. Nodal disease in the setting of metastatic renal cell carcinoma: Can a lymph node dissection alter outcomes?. J Clin Oncol (#386), 10/2012.
15. Zurita, AJ, Khajavi M, Wang X, Wood CG, Matin SF, Fiorentino S, McKee KS, Tran HT, Heymach J, Jonasch E. Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC). J Clin Oncol (#383), 10/2012.
16. Haddad H, Rini BI, Jonasch E, Tannir NM, Dreicer R, Garcia JA, Wood LS, Elson P. Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol (#4609), 10/2012.
17. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Dykema K, Petillo D, Teh BT, Tannir NM, Hung M-C, Jonasch E. Regulation of SETD2, a histony methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol (#368), 10/2012.
18. Ding Z, German P, Bai S, Gao M, Sobieski MM, Stephan CC, Mills GB, Jonasch E. Results of a high-throughput screen to identify compounds that modulate VHL proteostasis. J Clin Oncol (#369), 10/2012.
19. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experieince. J Clin Oncol (#4615), 10/2012.
20. Jonasch E, Lara P, Tannir NM. A randomized phase II study of MK-2206 in comparison with everolimus in refractory renal cell carcinoma.(NCI 8727). J Clin Oncol (#TPS192), 10/2011.
21. Jonasch E, Alvarez K, Peterson L, Tannir NM, Sircar K, Tamboli P, Monzon FA. Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma. J Clin Oncol (#339), 10/2011.
22. Cauley DH, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol (#332), 10/2011.
23. Ho TH, Wang F, Hoang A, Tamboli P, Jonasch E. Fibroblast growth factor receptor 1 (FGFR1) expression and activation in clear cell renal cell carcinoma (ccRCC). J Clin Oncol 29 (#e15015), 10/2011.
24. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol (#346), 10/2011.
25. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir MN. Metastatic RCC treated with pazopanib after progression on other targeted agents a single-institution experience. J Clin Oncol (#351), 10/2011.
26. Tannir NM, Lim ZD, Rao P, Tamboli P, Atkinson B, Vaishampayan U, Plimack E, Rathmell K, Jonasch E. Outcome of patients (pts) with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. J Clin Oncol (#386), 10/2011.
27. Verma J, Jonasch E, Allen P. Tannir NM, Mahajan A. Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: A retrospective review. J Clin Oncol (#340), 10/2011.
28. Atkinson BJ, Perpich J, Tannir NM, Jonasch E. Schedule modifications and treatment outcomes for sunitinib-related adverse events. J Clin Oncol (#e15115), 11/2010.
29. Jonasch E, Bair A, Chen Y, Rini BI. Axitinib with or without dose titration as first-line therapy for metastatic renal cell carcinoma (mRCC). J Clin Oncol (#TPS235), 10/2010.
30. Monzon FA, Alvarez K , Amato RJ, Peterson L, Shen SS, Hernandez-McClain J, Sircar K, Tamboli P, Tannir NM, Jonasch E. Chromosomal imbalances as biomarkers for recurrence and antiangiogenic resistance in clear cell renal cell carcinoma. J Clin Oncol (#e15012), 10/2010.
31. Bex A, Jonasch E, Dreese F, de Hoog C, Dellemijn T, Griffioen A W. Presurgical bevacizumab and sunitinib induced changes in primary clear cell renal tumor tissue. J Clin Oncol (#4607), 10/2010.
32. Jonasch E, Wood CG, Pagliaro LC, Corn PG, Aparicio A, Marcott VD, Matin SF, Tannir NM. Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis. J Clin Oncol (#e15083), 10/2010.
33. Plimack ER, Jonasch E, Bekele BN, Qiao W, Ng CS, Tannir NM. Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. J Clin Oncol (#4604), 10/2010.
34. Matin SF, McCutcheon IE, Gombos DS, S. Waguespack, N. M. Tannir, Wen S, Davis DW, Smith LA, Fuller G, Jonasch E. Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies. J Clin Oncol (#3040), 10/2010.
35. Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol (#4606), 10/2010.
36. Atkinson BJ, Wilhelm KL, Khakoo AY, Tannir NM, Jonasch E. A retrospective evaluation of antiangiogenic therapy induced hypertension in metastatic renal cell carcinoma. J Clin Oncol, 5/2010.
37. Abel EJ, Tannir NM, Culp SH, Matin SF, Jonasch E, Wood CG. Does targeted therapy result in reliable and meaningful primary tumor downstaging in patients with metastatic renal cell carcinoma?. J Clin Oncol. e-Pub 3/2010.
38. Pagliaro LC, Tannir NM, Thall PF, Ashe R, Perez CA, Jonasch E. Phase II study of be va cizumab, gemcitabine, and capecitabine treatment for metastatic or unresectable sarcomatoid renal cell carcinoma (SRCC). J Clin Oncol. e-Pub 3/2010.
39. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with systemic therapy without cytoreductive nephrectomy. J Clin Oncol 27(15s) (#e16035), 5/2009.
40. Atkinson B, Hart J, Lin E, Tannir N, Jonasch E. Patients characteristics associated with dose-limiting sunitinib adverse events. J Clin Oncol 27(15s) (#e16110), 5/2009.
41. Johnson ED, Tannir NM, Olejeme KA, Logothetis CJ, Jonasch E. Survival benefit in bevacizumab based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol 27(15s) (#e16096), 5/2009.
42. Miller L, Lal LS, Tannir NM, DaCosta Byfield S, Atkinson B, Feng C, Lau JK, Yin L, Jonasch E. Treatment of poor-risk metastatic renal carcinoma patients with combination gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. J Clin Oncol 27(15s) (#e16112), 5/2009.
43. Matin SF, McCutcheon IE, Gombos DS, Waguespack SG, Wen S, Smith LA, Zhang Y, Davis DW, Fuller G, Jonasch E. Treatment of VHL patients with subitinib: Clinical observations and translational studies. J Clin Oncol 27(15s) (#e22047), 5/2009.
44. Heymach J, Jonasch E, Wang X, DU DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ. A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15s) (#5114), 2009.
45. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(15s) (#5004), 2009.
46. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26(15s) (#5093), 2008.
47. Dubauskas Z, Kunishige J, Prieto VG, Hwu P, Jonasch E, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: a single institution experience. J Clin Oncol 26(15s) (#16101), 2008.
48. Plimack ER, Tannir NM, Bekele BN, Lin E, Jonasch E. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. Genitourinary Cancers Symposium 26(15s) (#5106), 2008.
49. Araujo JC, Jonasch E, Tannir N, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26(15s) (#5106), 2008.
50. Jonasch E, Wood CG, Matin S, Tamboli P, Do K, Pagliaro LC, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma. J Clin Oncol 26(15s) (#5104), 2008.
51. Tsavachidou D, Tannir N, Thomas C, Mills G, Jonasch E. Reverse-phase protein array marker evaulation of protein expression patterns related to anti-angiogensis. J Clin Oncol 26(15s) (#16016), 2008.
52. Plimack E, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal carcinoma (ncc-RCC): a phase II study. J Clin Oncol 26(15s) (#5112), 2008.
53. Jonasch E, Corn P, Ash RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 25(18s) (#5104), 2007.
54. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin S and Jonasch E. von Hippel-Lindau gene mutation status is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. J Clin Oncol 25(18s) (#15522), 2007.
55. Gao X, Reddy P, Dhanda K, Gondek K, Yeh YC, Stadler WM, Jonasch E. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol 24(18s) (#4604), 2006.
56. Jonasch E, Tsavachidou D, Wood C, Tamboli P, Tu S, Thomas C, Do KA, Matin S, Tannir NM. Presurgical treatment of metastatic renal cell carcinoma patients with bevacizumab and erlotinib: preliminary efficacy and biomarker data. European J of Can Suppl 4(12) (#80), 2006.
57. Srinivas S, Stadler WM, Bukowski R, Figlin R, Hayes T, Yankee EW,Jonasch E. Talactoferrin alfa may prolong progression-free survival in advanced renal cell carcinoma patients. J Clin Oncol 24(18s) (#4600), 2006.
58. Tannir NM, Jonasch E, McMicheal C, Wang X, Wooten L, Ng S. A phase II trial of gemcitabine plus capecitabine (GX) in patients with advanced renal cell cancer (mRCC) previously treated with immunotherapy. J Clin Oncol 23(16s) (#4598), 2005.
59. Jonasch E, Tu S-M, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke A, Wen S, Wen S, General R,Lin S-H, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma; a phase II study. J Clin Oncol 23(16s) (#445s), 2005.
60. Jonasch E, Wen S, Thomas C, McDonnell T. Concordance between PTEN and p27 staining in primary and metastatic samples in a renal carcinoma tissue microarray. In: Proc Amer Assoc Cancer Res 46 (#3092), 2005.
61. Rodney AJ, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer with prior taxane exposure. J Clin Oncol 23(16s) (#4750), 2005.
62. Tannir NM, Wang X, Ng CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Cohen L, Millikan RE. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as front-line therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 23(14s) (#4607), 2004.
63. Linette G, Jonasch E, Longerich S, Yang S, Webb I, Szczepiorkowski Z, Cheung A, Fee S, Haluska F. Phase I study of therapy with peptide-pulsed autologous dendritic cells for advanced melanoma. J Clin Oncol 19 (#1833), 2000.

Book Chapters

1. Jonasch E, Dayyani F. Chemotherapy and Targeted Therapies/Biological for Renal Cell Carcinoma. In: Image-Guided Cancer Therapies: A Multiple-Disciplinary. Ed(s) DE Dupuy, Y Fong, WN McMullen. Springer: USA, 713-725, 2013. ISBN: 978-1-4419-0750-9.
2. Jonasch E, Walker CL. EGFR and HER2: Relevance in Renal Cell Carcinoma. In: Renal Cell Carcinoma Molecular Targets and Clinical Applications, 2nd. Ed(s) Bukowski RM, Figlin RA, Motzer RJ. Humana Press: New York, 287-03, 2009. ISBN: 978-1-58829-737-2.
3. Jonasch E, Tannir NM. Targeted Therapy in Renal Cell Carcinoma. In: Targeted Therapy in Cancer. Humana Press: New Jersey, 305-16, 2007. ISBN: 978-60327-423-4.
4. Jonasch E, Do KA, Logothetis C, McDonnell TJ. Issues and applications for tissue arrays in target and drug discovery. In: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development. John Wiley and Sons, Inc., 73-90, 2004.
5. Jonasch E, Matin S, Wood CG, Pagliaro LC. Renal Cell Carcinoma. In: MD Anderson Manual of Clinical Oncology. McGraw-Hill, 757-84, 2000. ISBN: 0-07-14199-1.
6. Jonasch E. Renal Neoplasia. In: Brenner and Rector’s The Kidney, 8th. Elsevier Science Publishers, 1342-67, 2000.
7. Jonasch E. Renal Neoplasia. In: Brenner and rector's The Kidney. Ed(s) Barry M. Brenner, MD, Glenn Chertow, MD, Philip Marsden, MD, Karl Skorecki, MD, Maarten Taal, MD, and Alan S.L. Yu, MD. Elsevier. Submitted.

Books (edited and written)

1. Lara, PN Jonasch, E. Ed(s) Lara, PN Jonasch, E. Kidney Cancer: Principles and Practice. 1, 1. Springer: USA, 2012. ISBN: 978-3642218576.

Grant & Contract Support

Title: To develop a screen for molecules that permit refunctionalization of mutated VHL protein and alter proteostasis.
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 8/1/2012 - 7/31/2013
 
Title: SINF Grant
Funding Source: U T MDACC
Role: Principal Investigator
Duration: 6/1/2012 - 5/31/2015
 
Title: High-Throughput Screen to Detect Molecules that Alter TRiC-VHL Binding Characteristics
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 8/1/2011 - 7/31/2012
 
Title: High throughput screen to detect molecules that alter TRiC-VHL binding characteristics
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/30/2010 - 9/29/2011
 
Title: Evaluation of FGF Receptor Activation State in Renal Cell Carcinoma.
Funding Source: Bristol Myers Squibb
Role: Principal Investigator
Duration: 7/9/2009 - 7/31/2011

Last updated: 4/9/2014